Stem cell research is sure to pay off eventually, but having control of over 300 patents related to many differing aspects of the process may be an even bigger prize.
Advanced Cell Technology, a stem cell research and development company, is making steady progress in a market destined to become the future of many medical options. Regardless of current United States policy, the company has legally overcome hurdles to be granted permission for phase II trials where its heart disease Myoblast process is concerned.
Obtained from a recent September 2007 acquisition, the Myoblast process helps to grow cells for transplant around the heart and has showed success in Phase I trial. Phase II trial is currently being arraigned with a national hospital system. Other areas where Advanced Cell Technology has development work progressing are eye and single cell biopsy techniques.
Although the company’s progress in procedural work is impressive, and may lead to substantial gains in the future, the company’s holding of 360 patents in a developing field could be even more enticing. There is no knowing how the market may develop with regard to these patents, but a keen eye on how they do play into overall market developments is an interesting question.
Considering the United States political climate, with regard to stem cells, the company has been foresighted enough to cultivate an extensive international network of companies and researchers. Regardless of how the United States situation works out, Advanced Cell Technology is positioned for whatever may come.
Let us hear your thoughts below: